medigraphic.com
Instituto Nacional de Salud Pública

2020, Number 2

<< Back Next >>

salud publica mex 2020; 62 (2)

Dyslipidemia prevalence, awareness, treatment and control in Mexico: results of the Ensanut 2012

Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T, Rivera-Dommarco J, Hernández-Ávila M, Barquera S

Language: English
References: 24
Page: 137-146
PDF size: 278.01 Kb.


ABSTRACT

Objective. To describe in a national sample 1) the prevalence, awareness, treatment and control of dyslipidemias 2) the prevalence of dyslipidemias through previous national surveys. Materials and methods. We analyzed data of the National Health and Nutrition Survey 2012, a representative cross-sectional study. Serum samples of 9 566 adults ≥20 years old with fasting ≥8 hours were analyzed for lipid fractions. Age-adjusted prevalences were calculated, by sociodemographic variables. Prevalence of awareness, treatment and control was estimated. A description of the dyslipidemia prevalence reported in previous surveys is reported. Results. Hypoalphalipoproteinemia and elevated LDL-C are the most prevalent dyslipidemias in Mexican adults. One in four adults had hypercholesterolemia at the moment of the interview without previous diagnosis. Awareness, treatment and control of dyslipidemia were 12.6, 3.7 and 3.1%, respectively. Conclusions. Dyslipidemias are the most prevalent risk factor for cardiovascular diseases in Mexico. Public policies to increase awareness, access to therapy and sustained control are urgently needed.


REFERENCES

  1. Institute for Health Metrics and Evaluation. GBD Compare [Internet]. Seattle: IHME, 2015 [cited November 21, 2018]. Available from: http:// vizhub.healthdata.org/gbd-compare

  2. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol. 1993;22(4):A6-13. https:// doi.org/10.1016/0735-1097(93)90455-A

  3. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743-53. Available from: https://www.ahajournals.org/ doi/10.1161/CIRCULATIONAHA.107.699579

  4. Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, et al. Comparison of the framingham and reynolds risk scores for global cardiovascular risk prediction in the multiethnic women’s health initiative. Circulation. 2012;125(14):1748-56.

  5. Sahle BW, Owen AJ, Chin KL, Reid CM. Risk prediction models for incident heart failure: a systematic review of methodology and model performance. J Card Fail. 2017;23(9):680-7. https://doi.org/10.1016/j. cardfail.2017.03.005

  6. Lozano R, Gómez-Dantés H, Pelcastre B, Ruelas M, Montañez J, Campuzano J, et al. Carga de la enfermedad en México, 1990-2010. Nuevos resultados y desafíos [Internet]. Cuernavaca: Secretaría de Salud, Instituto Nacional de Salud Pública, 2014. Available from: https://www.insp.mx/ images/stories/Produccion/pdf/150122_cargaEnfermedad.pdf

  7. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol. 2004;13(3):125-38. https:// doi.org/10.1016/S1054-8807(04)00004-3

  8. Posadas-Romero C, Tapia-Conyer R, Lerman-Garber I, Zamora-González J, Cardoso-Saldaña G, Salvatierra-Izaba B, et al. Cholesterol levels and prevalence of hypercholesterolemia in a Mexican adult population. Atherosclerosis. 1995;118(2):275-84.

  9. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res [Internet]. 2001;42(8):1298-307. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 11483632

  10. Barquera S, Flores M, Olaiz-Fernández G, Monterrubio E, Villalpando S, González C, et al. Dyslipidemias and obesity in Mexico. Salud Publica Mex. 2007;49(suppl 3):S338-47.

  11. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex [internet]. 2010;52 (suppl 1):S44-53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20585729

  12. Gutiérrez JP, Rivera-Dommarco JÁ, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales. Cuernavaca: Instituto Nacional de Salud Pública, 2013.

  13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem [Internet]. 1972;18(6):499-502. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4337382

  14. Stone NJ, Robinson JG, Lichtenstein AH, Bairey-Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol [Internet]. 2014;63(25):2889-934. Available from: https://linkinghub. elsevier.com/retrieve/pii/S0735109713060282

  15. Hernandez-Alcaraz C, Aguilar Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T, et al. Supplementary material. Dyslipidemia prevalence and trends. DRAFT VERS. Harvard Dataverse; 2019. p. 1-2. https://doi.org/10.7910/DVN/D3BA8V

  16. Goodman DS, Hulley SB, Clrak LT, Davis CE, Fuster V, LaRosa JC, et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med [Internet]. 1988;148(1):36-69. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte. 1988.00380010040006

  17. Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying atherogenic lipoproteins: Current and future challenges in the era of personalized medicine and very low concentrations of ldl cholesterol. a consensus statement from EAS and EFLM. Clin Chem. 2018;64(7):1006-33.

  18. Rivera JA, Pedraza LS, Aburto TC, Batis C, Sánchez-Pimienta TG, González de Cosío T, et al. Overview of the dietary intakes of the mexican population: results from the National Health and Nutrition Survey 2012. J Nutr [Internet]. 2016;146(9):1851S-1855S. Available from: https://academic. oup.com/jn/article/146/9/1851S-1855S/4584848

  19. Lu Y, Wang P, Zhou T, Lu J, Spatz ES, Nasir K, et al. Comparison of prevalence, awareness, treatment, and control of cardiovascular risk factors in China and the United States. J Am Heart Assoc [Internet]. 2018;7(3):1-16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29374046

  20. Medina C, Janssen I, Campos I, Barquera S. Physical inactivity prevalence and trends among Mexican adults: results from the National Health and Nutrition Survey (ENSANUT) 2006 and 2012. BMC Public Health [Internet]. 2013;13(1):1063. Available from: http://bmcpublichealth.biomedcentral. com/articles/10.1186/1471-2458-13-1063

  21. Medina C, Tolentino-Mayo L, López-Ridaura R, Barquera S. Evidence of increasing sedentarism in Mexico City during the last decade: Sitting time prevalence, trends, and associations with obesity and diabetes. PLoS One. 2017;12(12):e0188518. https://doi.org/10.1371/journal.pone.0188518

  22. Berra K. Lipid-lowering therapy today. J Cardiovasc Nurs [Internet]. 2008;23(5):414-21. Available from: http://content.wkhealth.com/linkback/ openurl?sid=WKPTLP:landingpage&an=00005082-200809000-00007

  23. Schwiesow SJ, Nappi JM, Ragucci KR. Assessment of compliance with lipid guidelines in an Academic Medical Center. Ann Pharmacother [Internet]. 2006;40(1):27-31. Available from: http://journals.sagepub.com/ doi/10.1345/aph.1G303

  24. Zafrir B, Cohen S. Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Eur J Intern Med [Internet]. 2006;17(7):495-9. https://doi.org/10.1016/j.ejim.2006.03.005




2020     |     www.medigraphic.com